JP4579564B2 - Wrinkle improving agent - Google Patents
Wrinkle improving agent Download PDFInfo
- Publication number
- JP4579564B2 JP4579564B2 JP2004074092A JP2004074092A JP4579564B2 JP 4579564 B2 JP4579564 B2 JP 4579564B2 JP 2004074092 A JP2004074092 A JP 2004074092A JP 2004074092 A JP2004074092 A JP 2004074092A JP 4579564 B2 JP4579564 B2 JP 4579564B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- wrinkle
- improving agent
- wrinkles
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Description
本発明は、老化に伴い、特に露光部位に発生するシワの改善効果に優れ、皮膚を皮膚科学的および美容的に健やかな状態に保つ効果を有するピペリン酸を含有するシワ改善剤に関する。 The present invention relates to a wrinkle improving agent containing piperic acid, which has an excellent effect of improving wrinkles generated at an exposed site with aging, and has an effect of keeping the skin in a dermatological and cosmetically healthy state.
ヒトをはじめとするすべての生物の臓器は、誕生して成長した後、加齢と伴に徐々に衰え、やがて機能停止し、機能停止した部分がある一定以上になると死に至る。その機能が徐々に衰えて行く状態を老化と呼んでいる。皮膚は、まわりの環境から直接影響を受けており、生体内部の環境を維持する重要な機能を持っているため全てが機能停止に至ることはあまりないが、シワ、シミ、くすみ、タルミなど老化徴候が顕在化しやすい臓器であり、日光に暴露される露光部位では特に顕著である。 Organs of all living organisms including humans are born and grow, then gradually decline with age, eventually stop functioning, and die when a certain part of the function is stopped. A state in which the function gradually declines is called aging. The skin is directly affected by the surrounding environment, and since it has an important function to maintain the environment inside the living body, it is not likely that everything will stop functioning, but aging such as wrinkles, spots, dullness, and tarmi This is an organ in which signs are easily manifested, and is particularly prominent in exposed areas exposed to sunlight.
皮膚の老化が進行すると、酸化ストレスなどの刺激に対する防御が弱まり、皮膚内部環境を乱す原因となり、さらに老化を進める。特に、露光部位では紫外線照射などが原因となる強い酸化ストレスに常に曝されていることから、老化の進行が顕著である。このような皮膚の変化を光老化と呼んでおり、そのような皮膚では、真皮の大多数を占める構成成分であるコラーゲンが減少することにより、皮膚表面でシワが深く大きくなるなど美容上も好ましくない状態となる。 As skin aging progresses, defense against stimuli such as oxidative stress is weakened, causing the internal environment of the skin to be disturbed and further aging. In particular, since the exposed part is constantly exposed to strong oxidative stress caused by ultraviolet irradiation or the like, the progress of aging is remarkable. Such skin changes are called photoaging. In such skin, collagen, which is a constituent component of the majority of the dermis, decreases, and wrinkles deepen and become larger on the skin surface. No state.
光老化が進行した結果生じるシワに対して改善効果を有する物質として、米国ではレチノイン酸が処方箋薬として用いられているが、副作用が強く安全性にも問題があるため、我が国では承認に至っていない。また、体内に吸収された後レチノイン酸に転換され効果を発揮すると言われているレチノール（ビタミンＡ）や抗酸化およびコラーゲン合成促進効果を持つアスコルビン酸（ビタミンＣ）、抗酸化効果の強いトコフェロール（ビタミンＥ）などシワ改善物質として提案されているが、これらは十分に満足する効果が得られない欠点があった。したがって、これまでにシワを改善する物質として、十分に満足する効果を有し、安全性も有するものはなかった。 In the United States, retinoic acid is used as a prescription drug as a substance that has an improvement effect on wrinkles caused by the progress of photoaging, but it has not been approved in Japan because of its side effects and safety issues. . In addition, retinol (vitamin A), which is said to be converted into retinoic acid after being absorbed into the body and exert its effect, ascorbic acid (vitamin C) having an antioxidant and collagen synthesis promoting effect, and tocopherol having a strong antioxidant effect ( Vitamin E) and the like have been proposed as wrinkle-improving substances, but these have the disadvantage that a satisfactory effect cannot be obtained. Therefore, there has not been a substance that has a sufficiently satisfactory effect and safety as a substance for improving wrinkles so far.
また、従来のシワ改善剤は、化学合成によるものが多く、安全性の面からも多くの問題があった。一方、安全性の問題の生じにくい天然物質については、ビタミンを除きほとんど知られておらず、しかも充分に効果を発揮するものは得られていなかった。さらに、レチノールなどの天然のシワ改善剤は、光安定性に著しく欠けるものが多く、たとえ効果を有していても、製剤中で速やかに分解されるなど、製剤への配合が困難な物質がほとんどであった。 Further, many conventional wrinkle improving agents are obtained by chemical synthesis, and there are many problems in terms of safety. On the other hand, natural substances that are less likely to cause safety problems are hardly known except vitamins, and those that are sufficiently effective have not been obtained. Furthermore, many natural wrinkle-improving agents such as retinol lack light stability, and even if they have an effect, there are substances that are difficult to be incorporated into the formulation, such as being rapidly degraded in the formulation. It was almost.
ピペリン酸（５−（３，４−メチレンジオキシフェニル）−２，４−ペンタジエン酸）は、コショウ科、バンレイシ科、センリョウ科植物抽出物の特定の画分に含まれている既知物質である。ピペリン酸およびその誘導体の応用については、紫外線吸収剤（特許文献１および特許文献２参照）、皮膚病の治療（特許文献３参照）としての提案がなされているが、シワの改善効果についてはなんら検討がなされていなかった。 Piperic acid (5- (3,4-methylenedioxyphenyl) -2,4-pentadienoic acid) is a known substance contained in certain fractions of Pepperaceae, Vanillaceae, and Coleoptera plant extracts . As for the application of piperic acid and its derivatives, proposals have been made for ultraviolet absorbers (see Patent Literature 1 and Patent Literature 2) and treatment of skin diseases (see Patent Literature 3). There was no consideration.
本発明の目的は、老化により、特に露光部位で顕著に顕在化するシワの改善効果に優れ、美容的にも健やかな皮膚に保つ効果に優れ、安全性や安定性にも優れたシワ改善剤を提供することにある。 The object of the present invention is to improve wrinkles that are remarkably manifested in aging, especially in exposed areas, to keep skin healthy and cosmetically, and to improve wrinkles. Is to provide.
本発明者らは、上記のようなことから鑑みて鋭意研究を行った結果、ピペリン酸含有のシワ改善剤が老化により、特に露光部位で顕著に出現するシワを改善し、美容的にも皮膚を健やかに保つ効果および安全性、安定性に優れることを確認して本発明を完成するに至った。すなわち、本願発明は、下記化学式１（式中、Ｍは水素原子又は塩形成が可能な陽イオンを表す。）で表されるピペリン酸又はその塩を配合することを特徴とするシワ改善剤にある。また本願第２の発明は上記シワ改善剤を配合することを特徴とする皮膚外用剤にある。
本発明は、加齢に伴い特に露光部位に発生するシワの改善効果に優れ、皮膚を皮膚科学的および美容的に健やかな状態に保つシワ改善剤を提供することができる。 INDUSTRIAL APPLICABILITY The present invention can provide a wrinkle improving agent that is excellent in improving wrinkles that occur particularly in exposed areas with aging and that keeps the skin in a dermatological and cosmetically healthy state.
以下、本発明の実施の形態を詳述する。前記のごとく、ピペリン酸は、コショウ科、バンレイシ科、センリョウ科植物抽出物の特定の画分に含まれていることが公知である。本発明で用いられるピペリン酸の製造方法は、上記の植物から有機溶媒、例えばメタノール、エタノール、プロピルアルコール、イソプロピルアルコール、ブタノール等の低級アルコールおよび含水低級アルコール或いは１，３−ブチレングリコール等の多価アルコール等および含水多価アルコール或いは、アセトン、酢酸エチル、アセトン等の各種有機溶媒により抽出可能である。 Hereinafter, embodiments of the present invention will be described in detail. As mentioned above, it is known that piperic acid is contained in specific fractions of pepper, vanilla, and lepidopterous plant extracts. The method for producing piperic acid used in the present invention is obtained from the above plant using organic solvents such as lower alcohols such as methanol, ethanol, propyl alcohol, isopropyl alcohol and butanol and lower alcohols containing water or polyvalent such as 1,3-butylene glycol. Extraction can be performed with alcohol or the like and water-containing polyhydric alcohol or various organic solvents such as acetone, ethyl acetate, and acetone.
また、本発明で用いるピペリン酸はピペロナール（ヘリオトロピン）から一般的な有機合成法を用いて合成することや、胡椒に多く含まれるピペリンを加水分解することにより得ることもできるが、これらに限定されるものではない。 Piperic acid used in the present invention can be synthesized from piperonal (heliotropin) using a general organic synthesis method, or can be obtained by hydrolyzing piperine contained in a large amount of pepper, but is not limited thereto. Is not to be done.
ピペリン酸と塩形成が可能な陽イオンとしては、アルカリ金属、アルカリ土類金属、アンモニウムイオン、有機アンモニウムイオンが挙げられる。有機アンモニウムイオンとしては、モノエタノールアミン、ジエタノールアミン、トリエタノールアミン、モノプロパノールアミン等の有機アミンが使用可能である。 Examples of the cation capable of forming a salt with piperic acid include alkali metals, alkaline earth metals, ammonium ions, and organic ammonium ions. As the organic ammonium ion, organic amines such as monoethanolamine, diethanolamine, triethanolamine, and monopropanolamine can be used.
本発明におけるピペリン酸の配合量は、シワ改善剤の総量を基準としてそれぞれ０．００１〜１０．０質量％（以下、単に％と記する）が好ましい。特に好ましくは、０．５〜
２．０％である。これら各々の下限未満の配合量では、本発明の目的とする効果が十分でなく、一方、上限を越えてもその増加分に見合った効果の向上がなく好ましくない。
The compounding amount of piperic acid in the present invention is preferably 0.001 to 10.0% by mass (hereinafter simply referred to as%) based on the total amount of the wrinkle improving agent. Particularly preferably, 0.5 to
2.0%. If the blending amount is less than the lower limit of each of these, the intended effect of the present invention is not sufficient.
本発明のシワ改善剤は、皮膚外用剤として皮膚化粧料はもとより、医薬品や入浴剤等にも適用でき、剤型的には例えばローション類、乳液類、クリーム類、パック類等とすることができる。 尚、本発明のシワ改善剤には上記の他に色素、香料、防腐剤、界面活性剤、顔料、抗酸化剤等を本発明の目的を達成する範囲内で適宜配合することができる。 The wrinkle-improving agent of the present invention can be applied not only to skin cosmetics but also to pharmaceuticals and baths as external preparations for skin, and the dosage form may be, for example, lotions, emulsions, creams, packs, etc. it can. In addition to the above, a coloring matter, a fragrance, a preservative, a surfactant, a pigment, an antioxidant and the like can be appropriately blended with the wrinkle improving agent of the present invention within a range that achieves the object of the present invention.
以下、実施例及び比較例に基づいて本発明を詳説する。 Hereinafter, the present invention will be described in detail based on examples and comparative examples.
実施例１（ピペリン酸配合シワ改善剤）
ピペリン酸を１．０％配合したシワ改善剤を、光老化させた皮膚に適用した場合のシワ改善効果を以下の試験方法により調べた。
Example 1 (piperic acid-containing wrinkle improving agent)
The wrinkle improving effect when a wrinkle improving agent containing 1.0% piperic acid was applied to photoaged skin was examined by the following test method.
（試験方法）
１． 試験動物
試験開始時１０週齢のヘアレスマウス１群１０匹を用いた。
(Test method)
1. Test animals A group of 10 hairless mice aged 10 weeks at the start of the test was used.
２． シワ改善効果の評価方法
２−１．光老化条件
光老化は、ＵＶＡとＵＶＢを１日１回、週５回、８週間照射することで誘発させた。照射量は、ＵＶＡが２０Ｊ／ｃｍ２、２５Ｊ／ｃｍ２、３０Ｊ／ｃｍ２、ＵＶＢが２０ｍＪ／ｃｍ２、３０ｍＪ／ｃｍ２、４０ｍＪ／ｃｍ２と、１週ごとに照射量を増量し、３週目以降は最大量を照射した。
2. 2. Evaluation method of wrinkle improvement effect 2-1. Photoaging conditions Photoaging was induced by irradiating UVA and UVB once a day, 5 times a week for 8 weeks. Irradiation dose, UVA is increased with 20J / cm 2, 25J / cm 2, 30J / cm 2, UVB is 20mJ / cm 2, 30mJ / cm 2, 40mJ / cm 2, an irradiation amount for each 1 week, 3 After week, the maximum dose was irradiated.
２−２．評価方法
シワ改善効果はシワスコア及び真皮コラーゲン量により評価した。
シワスコア：Ｂｉｓｓｅｔｔらの方法（Ｐｈｏｔｏｃｈｅｍ Ｐｈｏｔｏｂｉｏｌ ４６：
３６７−３７８、 １９８７）に従って採点した。すなわち、シワの大きさ及び深さを肉眼で総合的に評価し、「大きく深いシワが確認できる」を３、「シワが確認できる」を２、「シワが確認できない」を１、「正常なキメが観察される」を０と４段階で採点した。真皮コラ−ゲン量：全層皮膚を採取してポリトロンホモジナイザー（ＫＩＮＥＭＡＴＩＣＡ社製）で破砕後、コラーゲン画分を抽出して酸加水分解後、ヒドロキシプロリン含有量をアミノ酸分析装置（日本分光製）を用いて定量した。１ｃｍ２当たりのヒドロキシプロリン量を真皮コラーゲン量の相対的指標とした。
2-2. Evaluation method The wrinkle improvement effect was evaluated by the wrinkle score and the amount of dermal collagen.
Wrinkle score: Bissett et al. (Photochem Photobiol 46:
367-378, 1987). That is, the size and depth of the wrinkle are comprehensively evaluated with the naked eye, 3 indicating that “a large and deep wrinkle can be confirmed”, 2 indicating “a wrinkle can be confirmed”, 1 indicating “a wrinkle cannot be confirmed”, and “normal” The texture is observed "was scored on a scale of 0 and 4. Dermal collagen amount: All skin layers are collected and crushed with a Polytron homogenizer (KINEMATICA), then the collagen fraction is extracted, acid hydrolyzed, and the hydroxyproline content is determined using an amino acid analyzer (manufactured by JASCO). And quantified. The amount of hydroxyproline per cm 2 was used as a relative indicator of the amount of dermal collagen.
３．試験操作
５０％エタノール水溶液（基剤）に、ピペリン酸を１．０％配合した試料を調製した（実施例１）。基材のみの試料を比較例１とした。評価試料０．１ｍＬをヘアレスマウスの背部皮膚（直径約２．５ｃｍ）に１日１回、１週間に５回の頻度で、ＵＶ照射開始後５週目から照射終了後４週目まで塗布した。そして、最終塗布終了後にシワスコアを採点した。屠殺後、皮膚を採取し、コラーゲン含有量（１ｃｍ２当たりのヒドロキシプロリン量）を測定した。
3. Test Procedure A sample was prepared by mixing 1.0% piperic acid in a 50% ethanol aqueous solution (base) (Example 1). A sample having only the substrate was designated as Comparative Example 1. An evaluation sample (0.1 mL) was applied to the back skin (diameter: about 2.5 cm) of a hairless mouse once a day at a frequency of 5 times a week from the fifth week after the start of UV irradiation to the fourth week after the end of irradiation. . And after completion | finish of the last application, the wrinkle score was scored. After sacrifice, the skin was collected and the collagen content (hydroxyproline amount per cm 2 ) was measured.
（試験結果）
実施例１のシワ改善剤のシワ改善効果（シワスコア値、真皮コラーゲン含有量）を、基剤のみを塗布した比較例１と比較することにより評価した。
(Test results)
The wrinkle improvement effect (wrinkle score value, dermal collagen content) of the wrinkle improving agent of Example 1 was evaluated by comparing with Comparative Example 1 in which only the base was applied.
（シワスコア評価結果）
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
群 シワスコア値（値は平均値±ＳＥ）
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
実施例１（ピペリン酸１．０％） ２．２５ ± ０．１９
比較例１（基剤のみ） ２．７５ ± ０．０９
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(Wrinkle score evaluation result)
--------------------------------
Group Wrinkle score (value is mean ± SE)
--------------------------------
Example 1 (piperic acid 1.0%) 2.25 ± 0.19
Comparative Example 1 (base only) 2.75 ± 0.09
--------------------------------
実施例１のピペリン酸塗布群は、基剤のみの比較例１と比較して、低いシワスコア値を示し、ピペリン酸が有効であることを示した。 The piperic acid application group of Example 1 showed a low wrinkle score value compared to Comparative Example 1 with only the base, indicating that piperic acid was effective.
（コラーゲン含有量測定結果）
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
群 コラーゲン含有量（値は平均値±ＳＥ）
（μｍｏｌ／ｃｍ２）
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
実施例１（ピペリン酸１．０％） ５．５２ ± ０．４５
比較例１（基剤のみ） ４．６７ ± ０．４０
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(Collagen content measurement result)
--------------------------------
Group Collagen content (values are mean ± SE)
(Μmol / cm 2 )
--------------------------------
Example 1 (piperic acid 1.0%) 5.52 ± 0.45
Comparative Example 1 (base only) 4.67 ± 0.40
--------------------------------
実施例１のピペリン酸塗布群は、基剤のみの比較例１と比較して、高いコラーゲン含有量（ヒドロキシプロリン量）を示し、光老化により減少する真皮コラーゲン量に対し、ピペリン酸が有効であることを示した。 The piperic acid application group of Example 1 shows a higher collagen content (hydroxyproline content) compared to Comparative Example 1 with only the base, and piperic acid is effective against the amount of dermal collagen decreased by photoaging. It showed that there is.
本試験の結果から実施例１のピペリン酸配合シワ改善剤が、比較例１と比較して明らかに、光老化によるシワを改善する効果を有することが分かる。 From the results of this test, it can be seen that the piperic acid-containing wrinkle improving agent of Example 1 clearly has an effect of improving wrinkles due to photoaging as compared with Comparative Example 1.
実施例２、比較例２（スキンローション）
下記組成のスキンローションを常法に従って調製し、それを試料として次の操作によって、シワ改善効果を評価した。５名の目尻にシワのある健常人（女性、４１〜６５歳）を被検者として、実施例２及び比較例１のスキンローションそれぞれを、左右のどちらかに決めて、朝洗顔後、及び夕方入浴後の１日２回、２ヵ月間（６０日）連続で目尻のシワの部分（各試料ごとに目尻を中心に約４ｃｍ２、２×２ｃｍ）に約０．２ｍＬずつ塗布してもらった。そして最終塗布後に左右の目尻部分の皮膚（シワ）の状態に関しアンケートに答えてもらった。
Example 2, Comparative Example 2 (skin lotion)
A skin lotion having the following composition was prepared according to a conventional method, and the wrinkle improvement effect was evaluated by using the sample as a sample by the following operation. Five healthy subjects with wrinkles in the outer corners of the eyes (female, 41 to 65 years old) were used as subjects, and the skin lotions of Example 2 and Comparative Example 1 were determined as either left or right, and after washing in the morning, and Twice a day after bathing in the evening for 2 months (60 days), apply 0.2 ml each to the wrinkles of the corners of the eyes (about 4 cm 2 , 2 x 2 cm centered around the corners of each eye). It was. Then, after the final application, they were asked to answer a questionnaire regarding the condition of the skin (wrinkles) on the left and right eye corners.
（組成）
原 料 成 分 配合量（質量％）
（１）ブチレングリコール ３０．０
（２）モノラウリン酸
ポリオキシエチレン（２０）ソルビタン ０．５
（３）プロピレングリコール ２０．０
（４）グリセリン １０．０
（５）メチルパラベン ０．１
（６）エタノール ７．０
（７）精製水 残 量
（８）ピペリン酸 ０．５（実施例２）
又は ０（比較例２）
(composition)
Raw material component Amount (% by mass)
(1) Butylene glycol 30.0
(2) Monolauric acid polyoxyethylene (20) sorbitan 0.5
(3) Propylene glycol 20.0
(4) Glycerin 10.0
(5) Methylparaben 0.1
(6) Ethanol 7.0
(7) Purified water remaining amount (8) Piperic acid 0.5 (Example 2)
Or 0 (Comparative Example 2)
アンケート結果をもとに、皮膚（シワ）の状態に関する各項目において、比較例２より
実施例２のスキンローションのほうが有効であると回答した人数を以下に示す。
Based on the questionnaire results, the number of respondents who answered that the skin lotion of Example 2 is more effective than Comparative Example 2 for each item related to the skin (wrinkle) state is shown below.
−−−−−−−−−−−−−−−−−−−
項目 人数（名）
−−−−−−−−−−−−−−−−−−−
シワが目立たなくなった ５
皮膚が柔らかくなった ４
皮膚にハリがでた ５
皮膚につやがでた ３
皮膚があかるくなった ４
−−−−−−−−−−−−−−−−−−−
-------------------
Item Number of people
-------------------
Wrinkles are less noticeable 5
The skin became soft 4
The skin got firmer 5
Shining on the skin 3
My skin became moist 4
-------------------
本試験結果から実施例２のスキンローションは、比較例２と比較して明らかにシワを改善しており、さらに、光老化により悪化する柔軟性や色調までもが改善されたことが分かる。また、本発明のスキンローションによる刺激や痒み等の皮膚の異常は認められなかった。 From this test result, it can be seen that the skin lotion of Example 2 clearly improved the wrinkles as compared with Comparative Example 2, and further improved the flexibility and color tone deteriorated by photoaging. In addition, skin abnormalities such as irritation and itching due to the skin lotion of the present invention were not observed.
実施例３（スキンクリーム）
下記組成のピペリン酸を配合したスキンクリームを常法により調製し、事前アンケートで目尻のシワを肌悩みとして挙げた２０名の健常人（女性、５０〜５５歳）に１週間以上使用してもらい、アンケート調査を行った。
Example 3 (skin cream)
A skin cream containing piperic acid with the following composition was prepared by a conventional method, and 20 healthy people (women, 50-55 years old) who listed wrinkles in the corner of their eyes as a skin trouble in a preliminary questionnaire were used for over a week. , Conducted a questionnaire survey.
（組成）
原 料 成 分 配合量（％）
（１）密ロウ ２．０
（２）ステアリン酸 ５．０
（３）ステアリルアルコール ５．０
（４）還元ラノリン ２．０
（５）スクワレン ２０．０
（６）モノステアレートソルビタン ３．０
（７）モノステアレート
ポリオキシエチレン（２０）ソルビタン ３．０
（８）プロピレングリコ−ル ５．０
（９）メチルパラベン ０．２
（１０）精製水 残 量
（１１）ピペリン酸 １．０
（１２）ピペリン酸塩 １．０
(composition)
Ingredients Component Amount (%)
(1) Thick wax 2.0
(2) Stearic acid 5.0
(3) Stearyl alcohol 5.0
(4) Reduced lanolin 2.0
(5) Squalene 20.0
(6) Monostearate sorbitan 3.0
(7) Monostearate Polyoxyethylene (20) Sorbitan 3.0
(8) Propylene glycol 5.0
(9) Methylparaben 0.2
(10) Purified water remaining amount (11) Piperic acid 1.0
(12) Piperate 1.0
実施例３のスキンクリームを使用してもらい、アンケート調査を実施した。その結果を以下に示す。尚、結果は、各項目ごとに使用前と比較して使用後にそう思うと回答した人数で示した。 A questionnaire survey was conducted using the skin cream of Example 3. The results are shown below. In addition, the result was shown by the number of people who responded that they thought so after use compared to before use for each item.
−−−−−−−−−−−−−−−−−−−
項目 人数（名）
−−−−−−−−−−−−−−−−−−−
シワが目立たなくなった １９
シワの大きさが減少した １７
シワの数が減少した ５
シワが増えた ０
−−−−−−−−−−−−−−−−−−−
-------------------
Item Number of people
-------------------
Wrinkles are less noticeable 19
Wrinkle size decreased 17
Number of wrinkles decreased 5
Increased wrinkles 0
-------------------
本試験結果から実施例３のスキンクリームは、使用前と比較してシワが目立たなくなったと実感しているヒトがほぼ全員で、その要因としてシワの数よりもシワの大きさを軽減することで、光老化によるシワを改善したことが分かる。また、本発明のスキンクリームによる刺激や痒み等の皮膚の異常は認められなかった。 From this test result, the skin cream of Example 3 is almost all humans who feel that wrinkles are less noticeable than before use, and the factor is that the size of wrinkles is reduced rather than the number of wrinkles. It can be seen that wrinkles due to photoaging were improved. In addition, skin abnormalities such as irritation and itching due to the skin cream of the present invention were not observed.
皮膚化粧料の他、外用剤として医薬品や入浴剤等に適用でき、剤型的には例えばロ−ション類、乳液類、クリ−ム類、パック類等とすることができ、皮膚の美容の面から非常に有用である。
In addition to skin cosmetics, it can be applied to pharmaceuticals and baths as external preparations, and can be formulated into lotions, emulsions, creams, packs, etc. It is very useful from the aspect.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004074092A JP4579564B2 (en) | 2004-03-16 | 2004-03-16 | Wrinkle improving agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004074092A JP4579564B2 (en) | 2004-03-16 | 2004-03-16 | Wrinkle improving agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005263638A JP2005263638A (en) | 2005-09-29 |
| JP4579564B2 true JP4579564B2 (en) | 2010-11-10 |
Family
ID=35088554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004074092A Expired - Fee Related JP4579564B2 (en) | 2004-03-16 | 2004-03-16 | Wrinkle improving agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4579564B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101787318B1 (en) * | 2017-04-03 | 2017-10-18 | 연세대학교 산학협력단 | Composition comprising Piperonal or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4970442B2 (en) * | 2006-06-30 | 2012-07-04 | 株式会社ノエビア | Whitening agent |
| JP5000964B2 (en) * | 2006-09-29 | 2012-08-15 | 株式会社コーセー | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression |
| JP5366358B2 (en) * | 2006-09-29 | 2013-12-11 | 株式会社コーセー | Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method |
| KR100846125B1 (en) * | 2007-03-30 | 2008-07-15 | 바이오스펙트럼 주식회사 | Compositions for improving skin wrinkle comprising piperine as an active ingredient |
| KR20140057040A (en) * | 2012-11-02 | 2014-05-12 | 연세대학교 산학협력단 | Compositions for improving skin aging comprising piperine compounds as active ingredients |
| CN106432173B (en) * | 2016-09-26 | 2018-09-25 | 内蒙古大学 | A kind of breast cancer targeted drug potassium pepper of new chemical synthesis |
| KR102012078B1 (en) * | 2017-08-02 | 2019-08-19 | 포항공과대학교 산학협력단 | An anti-aging or skin regenerating composition comprising piperonylic acid as an active ingredient |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2274058A (en) * | 1992-11-26 | 1994-07-13 | Eladevi Shah | Creams useful for treating psoriasis,exzema and lichen planus |
| JPH06336417A (en) * | 1993-03-31 | 1994-12-06 | Shiseido Co Ltd | Ultraviolet light absorber and external preparation for skin mixed with the same |
| WO1999025369A1 (en) * | 1997-11-17 | 1999-05-27 | Sederma S.A. | Compositions for cosmetic and dermopharmaceutical use containing a plant extract obtained from kava piper methysticum roots |
| JP2002520275A (en) * | 1998-07-13 | 2002-07-09 | ビー・テイー・ジー・インターナシヨナル・リミテツド | Skin disease treatment |
| US20040037895A1 (en) * | 2002-08-23 | 2004-02-26 | Alex Zhu | Methods of treating involuntary facial spasms and facial wrinkles |
-
2004
- 2004-03-16 JP JP2004074092A patent/JP4579564B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2274058A (en) * | 1992-11-26 | 1994-07-13 | Eladevi Shah | Creams useful for treating psoriasis,exzema and lichen planus |
| JPH06336417A (en) * | 1993-03-31 | 1994-12-06 | Shiseido Co Ltd | Ultraviolet light absorber and external preparation for skin mixed with the same |
| WO1999025369A1 (en) * | 1997-11-17 | 1999-05-27 | Sederma S.A. | Compositions for cosmetic and dermopharmaceutical use containing a plant extract obtained from kava piper methysticum roots |
| JP2002520275A (en) * | 1998-07-13 | 2002-07-09 | ビー・テイー・ジー・インターナシヨナル・リミテツド | Skin disease treatment |
| US20040037895A1 (en) * | 2002-08-23 | 2004-02-26 | Alex Zhu | Methods of treating involuntary facial spasms and facial wrinkles |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101787318B1 (en) * | 2017-04-03 | 2017-10-18 | 연세대학교 산학협력단 | Composition comprising Piperonal or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging |
| WO2018186641A1 (en) * | 2017-04-03 | 2018-10-11 | 연세대학교 산학협력단 | Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing piperonal or salt thereof as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005263638A (en) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4584991B2 (en) | Skin cosmetics and wrinkle improvers | |
| CA2907495C (en) | Antioxidant compositions and methods of using the same | |
| JP4567732B2 (en) | Skin cosmetics and wrinkle improvers | |
| JP4579564B2 (en) | Wrinkle improving agent | |
| JP2004091376A (en) | Epidermis keratinization normalizing agent and skin care preparation for external use for skin containing the same | |
| JP4934280B2 (en) | Wrinkle improving agent | |
| JP4488933B2 (en) | Wrinkle improving agent and external composition for skin | |
| JP4456918B2 (en) | Wrinkle improving agent | |
| JP3220275B2 (en) | Wrinkle improver | |
| JP3083105B2 (en) | Cosmetics | |
| JP4359197B2 (en) | Wrinkle improving agent and skin cosmetic | |
| JP3826132B2 (en) | Wrinkle improving agent | |
| JP2006248953A (en) | Wrinkle ameliorating agent and external composition for skin | |
| JP2005200357A (en) | Hair-fostering cosmetic | |
| JP5244284B2 (en) | Wrinkle improving agent | |
| JP2010024176A (en) | Wrinkle-improving agent | |
| JP4359235B2 (en) | Wrinkle improving agent and skin cosmetic | |
| Somwanshi et al. | Cosmetic Science | |
| JP2006232747A (en) | Ameliorant for wrinkle and skin cosmetic | |
| KR20220077185A (en) | Composition of skin external application for improving skin wrinkle and maufacturing method thereof | |
| JP2005220043A (en) | Wrinkle improving agent | |
| JP2014037448A (en) | Production method of skin external agent against aging | |
| JP2006124399A (en) | Composition for improving skin or hair | |
| JP2004307347A (en) | External preparation for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060328 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060822 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100428 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100824 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100826 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
| R151 | Written notification of patent or utility model registration |
Ref document number: 4579564 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |